Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5746922 | 0.99 | KCNH2 (0.48) | KCNH2SLC2A1HTR1ASLC6A4SSTR2 | |
| SCHEMBL5747539 | 0.87 | KCNH2 (0.49) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5744510 | 0.87 | KCNH2 (0.62) | KCNH2SLC2A1HTR1ASLC6A4SSTR2 | |
| SCHEMBL5746857 | 0.86 | SLC2A1 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5746846 | 0.86 | SLC2A1 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5746855 | 0.86 | SLC2A1 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5747963 | 0.86 | SLC2A1 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5747952 | 0.86 | SLC2A1 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 | |
| SCHEMBL5744836 | 0.85 | SSTR2 (0.48) | KCNH2SLC2A1SSTR2 | |
| SCHEMBL13356503 | 0.85 | KCNH2 (0.46) | KCNH2SLC2A1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885SLC2A1 4409/4885HTR1A 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.